Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHAPE: Fosgonimeton in Parkinson's Disease Dementia and Dementia with Lewy Bodies
NCT04831281Phase 2Terminated
- Sponsor
- LeonaBio
- Start
- Jan 2022
- Primary completion
- Apr 2023
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of fosgonimeton in Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB), sponsored by LeonaBio. Started Jan 2022; status: terminated.
02
Drugs
fosgonimeton
03
Conditions
Parkinson's disease dementia (PDD)dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on NCT04831281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04831281.